Evvy Raises $40M for Women’s Health Research

A vaginal microbiome test can answer an immediate patient question. At 100,000 patients, the same testing system begins to ask a wider one: what has medicine failed to measure across fertility, infection, inflammation, and reproductive health?

Evvy has raised an oversubscribed $40M Series B to work on both sides of that problem. Catalio Capital Management led the financing, which will support Evvy's consumer testing and care business while expanding the research platform built from its vaginal microbiome dataset.

The New York company plans to validate additional research, scale EvvyAI, extend distribution into clinicians' offices, and begin a deeper push into fertility and IVF. The round brings Evvy's total capital raised to nearly $60M, according to reporting published with the announcement.

What Evvy Announced

Evvy's $40M Series B was announced on September 15, 2026. Catalio led the round, with new participation from U.S. Fertility Innovation Fund, Rethink Impact, Muse Capital, and Alumni Ventures. Returning investors included Labcorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, and Foreground Capital, according to Beauty Independent's deal report.

Evvy did not disclose a valuation, security type, ownership terms, investor check sizes, board changes, or a detailed allocation of the proceeds. The nearly $60M total is consistent with Evvy's previously reported $5M Seed and $14M Series A plus the new $40M round, although the company has not published a transaction-by-transaction capital table.

Priyanka Jain is Evvy's co-founder and CEO. She built the company with co-founder and CMO Laine Bruzek and co-founder and Chief Science Officer Pita Navarro. Evvy launched its testing service in 2021 and now describes itself as a precision women's-health company built around the vaginal microbiome.

One Business Serves Patients While the Other Builds Evidence

Evvy's operating model joins a consumer health service to a research system. A customer uses an at-home swab, Evvy's laboratory analyzes the sample with metagenomic next-generation sequencing, and a licensed clinician reviews the result before it appears with interpretation and a care path in the patient's portal.

The company says its test identifies more than 700 bacteria and fungi and combines molecular results with more than 200 clinical data fields. Evvy also reports that it has served more than 100,000 patients, works with 3,000 practitioners, and has generated more than 15 peer-reviewed publications and abstracts. Those are company-reported figures, but Evvy's science materials identify published methodology and patient-outcomes studies behind the claims.

The research side depends on consent. Evvy says 96% of its patients opt to contribute anonymized data to clinical research, giving the company a dataset that can connect microbiome composition with symptoms, interventions, and health outcomes. That feedback loop is potentially valuable because women's-health datasets have historically been thinner and less representative than the biological questions researchers and clinicians are being asked to solve.

This structure also creates tension. Consumer investors can see a testing and care brand with a direct relationship to patients, while biotech investors can see a biomarker-discovery platform whose value depends on rigorous validation. Fortune reported that investors repeatedly asked Evvy to choose between those identities. The founders decided the relationship between them was the business.

Fertility Is the First Expansion Test

Evvy will direct part of the Series B toward fertility research. The company is conducting a prospective study with IVF clinics to examine whether markers of infection and inflammation in the vaginal microbiome are associated with implantation success or failure. It also intends to validate other studies now in development and expand the distribution of its consumer platform through medical practices.

The distinction between research and clinical proof matters. Microbiome patterns can be associated with infertility, IVF outcomes, preterm birth, recurrent pregnancy loss, or gynecological disease without establishing that a test or intervention can predict or change an individual patient's outcome. Evvy's current work is an effort to convert a large real-world dataset into validated biomarkers and care pathways, not a finished answer to those conditions.

EvvyAI sits inside that same boundary. The company launched the assistant in May to translate its research and microbiome data into guidance while directing questions that require medical judgment to clinicians. Scaling the interface may make the company's evidence easier to use, but the durable value will depend on the quality of the underlying data, the validation of new findings, and the way clinical teams act on them.

Why Catalio and U.S. Fertility Matter

Catalio invests across private, public, and credit markets in innovative healthcare. Its leadership position gives Evvy a life-sciences investor for the expensive part of the next stage: turning a proprietary dataset into evidence that can survive clinical scrutiny and support new diagnostics.

U.S. Fertility Innovation Fund adds a different kind of relevance. U.S. Fertility operates within the care environment Evvy wants to enter, and its participation connects the financing to physicians, clinics, and fertility workflows rather than leaving the research inside a consumer application. That relationship does not prove commercial adoption, but it puts an investor with operating exposure close to the validation work.

The returning investors carry Evvy's earlier history as a consumer and healthcare company. General Catalyst has backed Evvy since 2021, while Left Lane Capital and Labcorp Venture Fund were among the investors in the company's Series A. The mixed syndicate mirrors the company's central bet: patient access, laboratory science, clinical distribution, and research infrastructure have to advance together.

What the $40M Has to Make Possible

Evvy's financing arrives as women's health attracts more capital but growth-stage investors still ask companies to fit familiar categories. A consumer brand is legible. A diagnostics platform is legible. A company that intends to use one to compound the other has to prove the connection in operating results, published evidence, and clinical adoption.

The $40M gives Evvy room to keep those systems connected. It can expand the testing and care business that produces patient relationships, build the research infrastructure that studies the resulting data, and bring both into more clinician-led settings. The risk is that scale outruns validation or that the two halves compete for attention and capital before their relationship becomes commercially clear.

Evvy's founders chose the harder pitch because the scientific opportunity depends on the business model staying intact. The work now moves from a fundraising room into fertility studies, physicians' offices, laboratory workflows, and the next patient who needs more than another version of “unexplained.”